Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Rein Therapeutics Inc. (RNTX) had Return on Tangible Equity of 14.99% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-6.82M |
|
-- |
|
-- |
|
$6.87M |
|
$-6.87M |
|
$0.05M |
|
$-6.82M |
|
$-6.82M |
|
$-6.82M |
|
$-6.82M |
|
$-6.82M |
|
$-6.82M |
|
$-6.87M |
|
$-6.87M |
|
24.19M |
|
24.19M |
|
$-0.28 |
|
$-0.28 |
|
| Balance Sheet Financials | |
$6.60M |
|
$0.00M |
|
$50.88M |
|
$57.48M |
|
$7.69M |
|
-- |
|
$46.78M |
|
$54.47M |
|
$3.01M |
|
$-45.52M |
|
$3.01M |
|
23.05M |
|
| Cash Flow Statement Financials | |
$-12.59M |
|
-- |
|
$5.45M |
|
$12.87M |
|
$5.72M |
|
$-7.14M |
|
$0.52M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.86 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.59M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-226.79% |
|
|
Return on Tangible Equity |
14.99% |
-11.87% |
|
-226.80% |
|
$0.13 |
|
$-0.52 |
|
$-0.52 |
|